Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01915186
Other study ID # TY-02
Secondary ID
Status Completed
Phase N/A
First received July 31, 2013
Last updated December 19, 2013
Start date October 2010
Est. completion date September 2013

Study information

Verified date December 2013
Source The University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority Hong Kong: Ethics Committee
Study type Interventional

Clinical Trial Summary

The aim of the study is to evaluate the effect of DHEA supplement on ovarian reserve markers, ovarian response to gonadotrophins and cycle outcomes in patients with normal and poor ovarian reserve.

Study Hypotheses:

1. DHEA supplementation would improve markers of ovarian reserve and ovarian response to low dose FSH stimulation in both normal and poor responders

2. DHEA supplementation would improve IVF cycle outcomes


Description:

Consecutive patients attending subfertility clinic at the Department of Obstetrics and Gynaecology, Queen Mary Hospital who are scheduled for in-vitro fertilization (IVF) treatment will be recruited and written consent will be obtained.

Baseline assessment will be performed at early follicular phase (Day 2 or 3) with hormonal tests and ultrasound.

Subjects will be divided into two groups, the normal ovarian reserve group and the poor ovarian reserve group according to AFC. Poor ovarian reserve is defined as an AFC of less than 5, while normal ovarian reserve is defined as an AFC of 5 to 15 based on a previous study showing AFC being a good predictor of ovarian response (Tomas 1997). Subjects with normal ovarian reserve will be further subdivided into <35 and >/=35 years old while subjects with poor ovarian reserve will be further subdivided into first or subsequent cycles of IVF for subgroup analysis.

Subjects in both the normal and poor ovarian reserve group will be randomized according to a computer-generated randomization list in sealed envelopes to receive either DHEA at 25mg three times a day or placebo throughout the study period.

Any changes in hormonal profile and ovarian reserve will be assessed by the above-mentioned blood tests and pelvic ultrasound scans which will be repeated at early follicle phase (Day 2 or 3) in the two subsequent cycles.

After two months of DHEA/placebo treatment, the subjects will then be given a standard low dose ovarian stimulation with 75 IU intramuscular human menopausal gonadotrophin (HMG, MenogonĀ®, Ferring Pharmaceuticals) daily for 7 days. Blood tests and pelvic ultrasound scan will be repeated after 7 days of stimulation (ie. on day 10 or 11).

Hormonal profile and ovarian reserve will be repeated in follicular phase (D2 or 3) in the subsequent cycle, where all patients will then be offered a cycle of IVF treatment using antagonist protocol based on our standard departmental regimen. Cycle characteristic and pregnancy outcomes will be compared.

Analysis of ovarian reserve markers, ovarian response and IVF outcomes would be performed.


Recruitment information / eligibility

Status Completed
Enrollment 104
Est. completion date September 2013
Est. primary completion date January 2013
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

- Indicated for IVF treatment according to our standard department protocol

- Age < 40

- Regular menstrual cycles (21-35 days with </= 4 days inter-cycle variation)

- AFC not more than 15

Exclusion Criteria:

- Previous chemotherapy or pelvic irradiation

- Polycystic ovarian syndrome or polycystic ovaries

- On hormonal supplementation for any indication at the time of recruitment (e.g. estrogen, testosterone or DHEA)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Dietary Supplement:
Dihydroepiandrosterone (DHEA)
DHEA capsules are given at 25mg 3 times a day for 12 weeks

Locations

Country Name City State
Hong Kong University of Hong Kong Hong Kong

Sponsors (1)

Lead Sponsor Collaborator
The University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

References & Publications (1)

Gleicher N, Barad DH. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod Biol Endocrinol. 2011 May 17;9:67. doi: 10.1186/1477-7827-9-67. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Antral follicle count Compare the changes in antral follicle count after 12 weeks of DHEA supplementation prior to IVF treatment between the treatment and placebo groups after 12 weeks of DHEA No
Secondary Change in Follicular stimulating hormone (FSH) and anti-Mullerian Hormone (AMH) following DHEA supplementation; post stimulation estradiol level and number of follicles > 10mm, IVF outcomes, hormonal profile of follicular fluid Comparison on the ovarian reserve markers, response to low dose ovarian stimulation and IVF treatment outcomes between treatment and control groups after 12 weeks of DHEA No
See also
  Status Clinical Trial Phase
Withdrawn NCT02209168 - Differences in Ovarian Reserve Markers and Vitamin D Between Infertile Indian, Arabian and Caucasian Population
Completed NCT02341365 - Vitamin D Influence on Oocyte Donation N/A
Completed NCT02195947 - Antagonist Protocol in Poor Responders Phase 4
Completed NCT02185326 - Microflare Protocol in Poor Responders Phase 4
Completed NCT01897324 - IVF/ICSI Protocols in Poor Responders With Growth Hormone Phase 4
Recruiting NCT02294500 - Cohort Study to Evaluate Ovarian Function N/A
Recruiting NCT01662466 - Effect of Testosterone Treatment on Embryo Quality Phase 1/Phase 2
Enrolling by invitation NCT02179255 - Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF Phase 1/Phase 2